Kelm M, Strauer B E
Klinik für Kardiologie, Pneumologie und Angiologie, Medizinische Klinik und Poliklinik B, Heinrich-Heine-Universität Düsseldorf.
Internist (Berl). 2005 Mar;46(3):265-74. doi: 10.1007/s00108-005-1357-1.
The acute coronary syndrome comprises unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction. A successful and stable revascularisation of the infarct related vessel, and the prevention of the loss of myocardium are the main therapeutic targets, as cardiovascular mortality and long term quality of life are essentially determined by left ventricular function. The clinical diagnosis comprises clinical symptoms, ECG-changes, and cardiac troponins. Early percutaneous coronary intervention (PCI) has become the most common method of coronary revascularisation. If PCI is not available, systemic thrombolysis is an alternative after exclusion of contraindications. Parenteral anticoagulation with intravenous or subcutaneous heparines, antithrombotic therapy and HMG-CoA reductase inhibitors are the common secondary drug therapy. Moreover, to prevent left ventricular remodelling ACE-inhibitors, angiotension 2-receptor antagonists, and beta-blocker are indicated.
急性冠状动脉综合征包括不稳定型心绞痛、非ST段抬高型心肌梗死和ST段抬高型心肌梗死。梗死相关血管成功且稳定的血运重建以及预防心肌损失是主要治疗目标,因为心血管死亡率和长期生活质量主要由左心室功能决定。临床诊断包括临床症状、心电图变化和心肌肌钙蛋白。早期经皮冠状动脉介入治疗(PCI)已成为冠状动脉血运重建最常用的方法。如果无法进行PCI,在排除禁忌证后,全身溶栓是一种替代方法。静脉或皮下注射肝素进行胃肠外抗凝、抗血栓治疗和HMG-CoA还原酶抑制剂是常见的二级药物治疗。此外,为预防左心室重构,可使用血管紧张素转换酶抑制剂(ACE抑制剂)、血管紧张素2受体拮抗剂和β受体阻滞剂。